Patents by Inventor Balaram Ghosh
Balaram Ghosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11596691Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.Type: GrantFiled: November 6, 2020Date of Patent: March 7, 2023Assignee: The General Hospital CorporationInventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Publication number: 20210162048Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.Type: ApplicationFiled: November 6, 2020Publication date: June 3, 2021Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Patent number: 10828367Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.Type: GrantFiled: May 1, 2018Date of Patent: November 10, 2020Assignee: The General Hospital CorporationInventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Publication number: 20190070295Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.Type: ApplicationFiled: May 1, 2018Publication date: March 7, 2019Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Patent number: 9988343Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: GrantFiled: November 5, 2014Date of Patent: June 5, 2018Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh
-
Patent number: 9981038Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds are diazo compounds including a substituted or unsubstituted aryl or heteroaryl ring, wherein at least one of the rings is substituted with one or more HDAC targeting elements.Type: GrantFiled: March 13, 2014Date of Patent: May 29, 2018Assignee: The General Hospital CorporationInventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Publication number: 20160272579Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: November 5, 2014Publication date: September 22, 2016Inventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh
-
Patent number: 9302967Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.Type: GrantFiled: April 11, 2012Date of Patent: April 5, 2016Assignee: Council of Scientific & Industrial ResearchInventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Choudhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Pradyot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
-
Publication number: 20160022817Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds are diazo compounds including a substituted or unsubstituted aryl or heteroaryl ring, wherein at least one of the rings is substituted with one or more HDAC targeting elements.Type: ApplicationFiled: March 13, 2014Publication date: January 28, 2016Applicant: The General Hospital CorporationInventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
-
Patent number: 9085559Abstract: A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.Type: GrantFiled: December 31, 2010Date of Patent: July 21, 2015Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety, Arun Bandyopadhyay, Siddhartha Roy, Santu Bandyopadhyay, Rakesh Kamal Johri, Subhash Chander Sharma, Balaram Ghosh, Mabalirajan Ulaganathan, Sakshi Balwani, Bholanath Paul, Ashok Kumar Saxena
-
Publication number: 20140135393Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.Type: ApplicationFiled: April 11, 2012Publication date: May 15, 2014Applicant: Council of Scientific & Industrial ResearchInventors: Santu Bandyopadhyay, Balaram Ghosh, Parasuraman Jaisankar, Bikas Chandra Pal, Siddhartha Roy, Balaram Ghosh, Parasuraman Jaisankar, Bikas Pal, Nahid Ali, Siddhartha Roy, Bholanath Paul, Arjun Ram, Siddhartha Roy, Bholanath Paul, Arjun Ram, Ulaganathan Mabalirajan, Nahid Ali, Arun Bandopadhyay, Aditya Konar, Jayashree Bagchi Chakraborty, Indrani Chowdhury Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, Anirban Manna, Roma Sinha, Prayot Bhattacharya, Jayaraman Vinayagam, Deba Prasad Jana, Sushovan Chowdhury
-
Patent number: 8680288Abstract: The present invention relates to Pyridin-2-yl sulfanyl acid ester compounds having antiinflammatory properties. The present invention particularly relates to novel anti-inflammatory heterocyclic acid esters of Pyridin-2-yl sulfanyl having the structure of general formula 1 which have been screened for their antiinflammatory activity with respect to inhibition of adhesion of neutrophils, isolated from human peripheral blood, onto the surface of human umbilical vein endothelial cells (HU-VEC) as a result of inhibition of the cytokine-stimulated expression of cell adhesion molecule ICAM-1. The compound RS—Z, 3-(Pyridin-2-yl sulfanyl)-propionic acid pentyl ester (structure 1a, R1=H, R2=H, R3=CH2-COOC5H11) was found to be most effective for ICAM-1 and neutrophil adhesion inhibition and was found to effectively alleviate inflammation mediated by excessive leukocyte infiltration leading to inflammatory disorders or like conditions, such as acute lung injury and acute respiratory distress syndrome in mice.Type: GrantFiled: July 20, 2011Date of Patent: March 25, 2014Assignee: Council of Scientific & Industrial ResearchInventors: Jadab Chandra Sarma, Dilip Chandra Bora, Paruchuri Gangadhar Rao, Balaram Ghosh, Sakshi Balwani
-
Publication number: 20130131350Abstract: The present invention relates to Pyridin-2-yl sulfanyl acid ester compounds having antiinflammatory properties. The present invention particularly relates to novel anti-inflammatory heterocyclic acid esters of Pyridin-2-yl sulfanyl having the structure of general formula 1 which have been screened for their antiinflammatory activity with respect to inhibition of adhesion of neutrophils, isolated from human peripheral blood, onto the surface of human umbilical vein endothelial cells (HU-VEC) as a result of inhibition of the cytokine-stimulated expression of cell adhesion molecule ICAM-1. The compound RS—Z, 3-(Pyridin-2-yl sulfanyl)-propionic acid pentyl ester (structure 1a, R1=H, R2=H, R3=CH2-COOC5H11) was found to be most effective for ICAM-1 and neutrophil adhesion inhibition and was found to effectively alleviate inflammation mediated by excessive leukocyte infiltration leading to inflammatory disorders or like conditions, such as acute lung injury and acute respiratory distress syndrome in mice.Type: ApplicationFiled: July 20, 2011Publication date: May 23, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Jadab Chandra Sarma, Dilip Chandra Bora, Paruchuri Gangadhar Rao, Balaram Ghosh, Sakshi Balwani
-
Publication number: 20120283263Abstract: A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.Type: ApplicationFiled: December 31, 2010Publication date: November 8, 2012Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety, Arun Bandyopadhyay, Siddhartha Roy, Santu Bandyopadhyay, Rakesh Kamal Johri, Subhash Chander Sharma, Balaram Ghosh, Mabalirajan Ulaganathan, Sakshi Balwani, Bholanath Paul, Ashok Kumar Saxena
-
Patent number: 7858763Abstract: The present invention is related to the haplotypes of human Transforming Growth Factor Beta1 (TGF?1) and prediction of susceptibility for immunological disorders. More particularly the present study is the first study in any population, identifying novel protective and risk haplotypes of the TGF?1 gene The present invention also relates to allelic variants of the human Transforming Growth Factor Beta1 (TGF?1) gene. The said invention also provides primers and methods suitable for the detection of these haplotypes and allelic variants for the prediction of an individual's disease susceptibility, and/or the genetic analysis of the TGF?1 gene for immunological disorders, particularly asthma. A vital aspect of the present study provides a method for predicting susceptibility of individuals to immunological disorders, particularly asthma.Type: GrantFiled: June 6, 2005Date of Patent: December 28, 2010Assignee: Council of Scientific and Industrial ResearchInventors: Balaram Ghosh, Shilpy Sharma, Kamalpreet Nagpal
-
Publication number: 20070243539Abstract: Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and/or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma.Type: ApplicationFiled: October 25, 2006Publication date: October 18, 2007Inventors: Balaram Ghosh, Mamta Sharma, Jyotsna Batra
-
Publication number: 20060024706Abstract: The present invention is related to the haplotypes of human Transforming Growth Factor Beta1 (TGF?1) and prediction of susceptibility for immunological disorders. More particularly the present study is the first study in any population, identifying novel protective and risk haplotypes of the TGF?1 gene The present invention also relates to allelic variants of the human Transforming Growth Factor Beta1 (TGF?1) gene. The said invention also provides primers and methods suitable for the detection of these haplotypes and allelic variants for the prediction of an individual's disease susceptibility, and /or the genetic analysis of the TGF?1 gene for immunological disorders, particularly asthma. A vital aspect of the present study provides a method for predicting susceptibility of individuals to immunological disorders, particularly asthma.Type: ApplicationFiled: June 6, 2005Publication date: February 2, 2006Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, an Indian registered body incorporatedInventors: Balaram Ghosh, Shilpy Sharma, Kamalpreet Nagpal
-
Publication number: 20040191327Abstract: The present invention relates to a method of preventing and/or treating asthma in animals including humans using natural compound Luteolin, said method comprising administering therapeutically effective dose of the Luteolin and leading to level of IFN-gamma increasing to normal level, levels of IL-5, IL-4, and IgE decreasing to normal level, and further, said method inhibits airway constriction, and airway hyperreactivity.Type: ApplicationFiled: November 3, 2003Publication date: September 30, 2004Applicant: Council of Scientific and Industrial ResearchInventors: Balaram Ghosh, Moumita Das, Arjun Ram
-
Publication number: 20040106685Abstract: The present invention relates to a method of preventing and/or treating asthma in a subject, said method comprising step of administering effective pharmacological amount of parabromophenacyl bromide (PBPB) to the subject and also, a method of modulating levels of biomolecules to achieve the same.Type: ApplicationFiled: March 17, 2003Publication date: June 3, 2004Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Arjun Ram, Balaram Ghosh, Sharad Vishwanath Gangal
-
Patent number: RE49240Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: GrantFiled: March 11, 2020Date of Patent: October 11, 2022Assignee: The General Hospital CorporationInventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh